Trial Profile
Proof of Concept Study to Investigate Safety, Tolerability, Pharmacokinetics and the Impact on Pulmonary and Systemic Hemodynamics, Gas Exchange and Lung Function Parameters of a Single-dose of BAY63-2521 IR-tablet in Patients With COPD Associated Pulmonary Hypertension in an Non-randomized, Non-blinded Design
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary hypertension
- Focus Pharmacodynamics; Pharmacokinetics; Proof of concept
- Sponsors Bayer
- 09 Jun 2014 The results of this trial have been reported on the company website.
- 09 Jun 2014 New trial record